1-20 of 203 Search Results for

sulfonylurea

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
EISBN: 978-3-8055-9944-3
...) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2009; 30: 170-180 3. Marthinet E, et al: Severe congenital hyperinsulinism caused by a mutation in the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel impairing trafficking and function. J Clin...
Book Chapter
Series: Frontiers in Diabetes
Volume: 29
Published: 31 August 2020
10.1159/000506558
EISBN: 978-3-318-06734-7
... of sulfonylurea drugs to treat patients with type 2 diabetes occurred in 1956. Defining their mechanisms of action did not occur until the 1990s. The elucidation of the profound effects of thiazolidinediones through their activation of the transcription factor PPARγ (peroxisome proliferator-activated receptor...
Book Chapter
Series: Frontiers in Diabetes
Volume: 28
Published: 03 January 2020
10.1159/000480179
EISBN: 978-3-318-06612-8
..., while based on fetal growth as regards hepatocyte nuclear factor 4-alpha- and hepatocyte nuclear factor 1-alpha-MODY. Transplacental transfer of sulfonylureas also raises questions as to when insulin should be initiated in sulfonylurea-responsive forms of monogenic diabetes. At the moment, data...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
10.1159/000334464
EISBN: 978-3-8055-9944-3
... in understanding the molecular basis of K ATP channel activity, as well as the role of these channels in physiology and disease. K ATP channels are generated from coassembly of Kir6.2 pore-forming subunits with sulfonylurea receptor 1 (SUR1) regulatory subunits. They are inhibited by intracellular ATP...
Book Chapter
Series: Advances in Cardiology
Volume: 45
Published: 14 February 2008
10.1159/000115193
EISBN: 978-3-8055-8428-9
... Abstract Five types of oral antihyperglycemic drugs are currently approved for the treatment ofdiabetes: biguanides, sulfonylureas, meglitinides, glitazones and alpha-glucosidaseinhibitors. We briefly review the cardiovascular effects of the most commonly used antidiabeticdrugs in these groups...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
10.1159/000334485
EISBN: 978-3-8055-9944-3
... Abstract The beta-cell ATP-sensitive potassium (K ATP ) channel plays a key role in regulating insulin secretion by linking glucose metabolism to cell excitability. The channel is a protein complex composed of four Kir6.2 inwardly rectifying potassium channel subunits and four sulfonylurea...
Book Chapter
Series: Frontiers in Diabetes
Volume: 23
Published: 15 September 2014
EISBN: 978-3-318-02700-6
...-1439. 4. Becker ML, Visser LE, Trienekens PH, Hofman A, et al: Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008;83:288-292. 5. Sesti G, Marini MA, Cardellini M, Sciacqua A, et al: The Arg972 variant...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
EISBN: 978-3-8055-9944-3
... J: Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor (see comments). Science 1995; 270: 1166-1170 10. Nichols CG Shyng SL Nestorowicz A Glaser B Clement JP Gonzalez G Aguilarbryan L Permutt MA Bryan J: Adenosine diphosphate as an intracellular regulator...
Book Chapter
Series: Frontiers in Diabetes
Volume: 29
Published: 31 August 2020
10.1159/000506563
EISBN: 978-3-318-06734-7
... of humility that result from perceiving things within a larger context,” as described by Nancy C. Andreasen. Many milestones in diabetes were laid by non-diabetologists. Frederick Banting was a general surgeon, Marcel Janbon, an infectivologist, opened the way to sulfonylureas in 1942. Rosalyn Yalow...
Book Chapter
Series: Frontiers in Diabetes
Volume: 23
Published: 15 September 2014
EISBN: 978-3-318-02700-6
... of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993;16:1254-1261. 17. Gloyn AL, Pearson ER, Antcliff JF, et al: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2...
Book Chapter
Series: Frontiers in Diabetes
Volume: 29
Published: 31 August 2020
EISBN: 978-3-318-06734-7
... population. Diabetologia 1980;19:205–210. 36. Reaven GM: Role of insulin resistance in human diseases. Diabetes 1988;37:1595–1607. 37. Reaven GM, Johnston P, Hollenbeck CB, Skowronski R, Zhang JC, Goldfine ID, Chen YD: Combined metformin-sulfonylurea treatment of patients with non-insulin dependent...
Book Chapter
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
10.1159/000439369
EISBN: 978-3-318-05639-6
... Abstract An array of oral agents is available for the treatment of hyperglycaemia in type 2 diabetes. This systematic inventory focuses on ‘old' oral agents, including metformin, sulfonylureas (SUs), thiazolidinediones, alpha glucosidase inhibitors, and meglitinides. Twelve meta-analyses...
Book Chapter
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
10.1159/000439372
EISBN: 978-3-318-05639-6
... to sulfonylureas, causing significantly less hypoglycaemia and not inducing weight gain. Specific adverse effects have not been discovered yet, and cardiovascular safety has been demonstrated in respective studies. Sodium-glucose transporter-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) were...
Book Chapter
Series: Frontiers in Diabetes
Volume: 22
Published: 10 April 2014
10.1159/000357252
EISBN: 978-3-318-02598-9
... of hypoglycemia and glycemic instability. Hypoglycemic episodes associated with insulin or sulfonylurea therapy are more frequent and tend to be more severe and to last longer. Hypoglycemia is the consequence of impaired counterregulation and glucose recovery due to deficient glucagon secretion, blunted...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
10.1159/000334516
EISBN: 978-3-8055-9944-3
... the mechanisms of amino acid-stimulated insulin secretion (AASIS), including activating mutations of glutamate dehydrogenase (GDH), inactivating mutations of the ATP-sensitive potassium channel [sulfonylurea receptor 1 (SUR1) and Kir 6.2], and inactivating mutations of short-chain 3-hydroxyacyl-CoA dehydrogenase...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
EISBN: 978-3-8055-9944-3
... 4. Otonkoski T Ammala C Huopio H Cote GJ Chapman J Cosgrove K Ashfield R Huang E Komulainen J Ashcroft FM Dunne MJ Kere J Thomas PM: A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes 1999; 48...
Book Chapter
Series: Endocrine Development
Volume: 11
Published: 20 November 2007
10.1159/000111062
EISBN: 978-3-8055-8348-0
...). This is particularly important, since patients withKir6.2 and SUR1 defects can now be treated with oral sulfonylureas. Major advancementshave been obtained and continue to be made with respect to diagnosis and classification.Differentiation between transient and permanent neonatal diabetes can only be done afterlong...
Book Chapter
Series: Frontiers in Diabetes
Volume: 29
Published: 31 August 2020
10.1159/000506545
EISBN: 978-3-318-06734-7
... the effects of sulfonylurea with those of metformin, blood glucose decreases faster under monotherapy with glibenclamide than under metformin. However, in the long run metformin seems to be more effective; for example, the ADOPT study showed that after 5 years using sulfonylurea, a “late failure” occurred...
Book Chapter
Series: Frontiers in Diabetes
Volume: 25
Published: 19 April 2017
EISBN: 978-3-318-06025-6
..., Barak L, Javorkova J, Jamncova E, Ciljakova M, Hlava P, Michalek J, Flanagan SE, Pearson E, Hattersley AT, Ellard S, Klimes I: Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Enodcrinol...